Authors
Sarah Reppert, Katerina Andreev, Sandra Wittmann, and Susetta Finotto
Summary
Lung cancer is one of the most frequently occurring cancer types. Successful lung cancer therapies in patients require preliminary investigations of promising therapeutic reagents in animal models. This protocol describes a method to induce lung tumours in mice and to deliver an immunoregulatory molecule directly to the lung by intranasal application. Here we describe the usage of murine cell lines L1C2 and B16F10 for the induction of lung adenocarcinoma or metastatic melanoma respectively. In this model the tumour cells are injected intravenously in the tail vein of the mice. To apply therapeutic reagents locally in the lung during tumour growth, the mice are anaesthetized and the therapeutic molecule is applied drop by drop into the nose of the mouse at different time points after tumour induction. To monitor the outcome of the therapy tumour size can be defined by analyzing Haematoxilin/Eosin stained slices of the lung.Further details
The protocol was published on Protocol Exchange on 18 July 2012. To see the entire protocol, click on the source link.Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 285
- Comments 0